These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37429302)

  • 1. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
    Blay JY; Chevret S; Le Cesne A; Brahmi M; Penel N; Cousin S; Bertucci F; Bompas E; Ryckewaert T; Soibinet P; Boudou-Rouquette P; Saada Bouzid E; Soulie P; Valentin T; Lotz JP; Tosi D; Neviere Z; Cancel M; Ray-Coquard I; Gambotti L; Legrand F; Lamrani-Ghaouti A; Simon C; Even C; Massard C
    Lancet Oncol; 2023 Aug; 24(8):892-902. PubMed ID: 37429302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
    Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
    Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
    Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
    Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
    Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
    Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
    Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
    Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
    Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
    Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
    Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
    Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
    Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
    Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
    Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
    Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
    Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
    Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.